CAS: 3964-81-6; Azatadine

上下游产品

H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ol11-(1-methyl-piperidin-4-yl)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ol cycloheptapyridin-11-one5,6-Dihydro-11H-benzo5,6cyclohepta1,2-bpyridin-11-one N-tert-butyl-3-methylpyridine-2-carboxamide benzyl chloridecycloheptapyridine11-(1-phenoxycarbonyl-4-piperidylene)-5,6-dihydro-11H-benzo5,6cyclohepta1,2-bpyridine desmethylazatadine

📜8-氯-6,11-二氢-11-(1-甲基-4-哌啶叉)-5H-苯并[5,6]环庚烷[1,2-B]吡啶置于palladium 10% On Activated Carbon,氢气,溶剂黄146体系中,用 乙醇 作为反应溶剂,化学反应 20.0H,以87.5%的收率获得产物6,11-二氢-11-(1-甲基-4-哌啶亚基)-5H-苯并[5,6]环庚烷并[1,2-B]吡啶
参考文献:一种氯雷他定杂质的制备方法
标题:一种氯雷他定杂质的制备方法
摘要:本发明提供了一种氯雷他定杂质的制备方法,其包括:将甲基氯雷他定溶解在溶剂中,加入酸和催化剂,在氢气氛围中升温反应,然后降温,过滤,浓缩,纯化,得到式ⅱ所示的氯雷他定杂质,本发明的技术方案原料廉价易得,操作和后处理简单,反应条件温和,工艺稳定,收率高,重现性好.本发明的技术方案弥补了国内无其制备方法的空白,也能降低医药企业开发此药品的成本,其具有非常好的产业化应用前景.

专利信息

专利号:US-7919505-B2
优先权日:2006-07-11
标题 :Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
发明人：TING PAULINE C; LEE JOE F; FENG KUNG-I; REEDER MICHAEL R; TRZASKA SCOTT T; ZHU MAN; MAO CHEN; FILIPOV DIMITAR L; ZARKADAS DIMITRIOS N
权利人:SCHERING CORP
摘要:The present invention relates to the compound of the formula n nTo methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.

专利号:US-2011003780-A1
优先权日:2007-07-10
标题:Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof
发明人：ZHU MAN
权利人:SCHERING CORP
摘要:The present invention relates to the compound of the Formula I: n n n n n n n n n n and to methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to a particular crystalline form and processes of synthesis of the crystalline form. n IM=105109

专利号:US-7309799-B2
优先权日:2004-06-01
标 题:Methods for the synthesis of milnacipran and congeners thereof
发明人：BUCHWALD STEPHEN L; SWAGER TIMOTHY M; RARIY ROMAN V
权利人:COLLEGIUM PHARMACEUTICAL INC
摘要:One aspect of the present invention relates to methods for synthesizing milnacipran or congeners thereof. Another aspect of the present invention relates to asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof. The present invention also relates to methods for synthesizing intermediates useful in the non-asymmetric or asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof.

专利号:US-2003050319-A1
优先权日:2000-04-18
标题:Synthesis of intermediates useful in preparing tricyclic compounds

专利号:US-2005282898-A1
优先权日:2004-06-01
标 题 :Methods for the synthesis of milnacipran and congeners thereof

专利号:US-8697730-B2
优先权日:2007-10-26
标题 :5-lipoxygenase activating protein (FLAP) inhibitor
发明人：REWOLINSKI MELISSA VIRGINIA; SCHAAB KEVIN MURRAY; KING CHRISTOPHER DAVID; STOCK NICHOLAS SIMON
权利人:REWOLINSKI MELISSA VIRGINIA; SCHAAB KEVIN MURRAY; KING CHRISTOPHER DAVID; STOCK NICHOLAS SIMON; PANMIRA PHARMACEUTICALS LLC
摘要:Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.